Page 49«..1020..48495051..»

DtaS – Nanomedicine – Part 1

§ June 1st, 2011 § Filed under Nano Medicine Comments Off on DtaS – Nanomedicine – Part 1

Dr. Tejal Desai discusses nanomedicine, nanotoxicology, and all else nano at the April 21st Down to a Science event.

Read more:

DtaS - Nanomedicine - Part 1

Read the Rest...

Nanomedicine IGERT @ Northeastern

§ June 1st, 2011 § Filed under Nano Medicine Comments Off on Nanomedicine IGERT @ Northeastern

Northeastern graduate students Tatyana Chernenko, Yogesh Patel and Brian Plouffe discuss how the Integrative Graduate Education and Research Traineeship (IGERT) in Nanomedicine, one of two Northeastern IGERT programs, helps them use nanotechnology to develop new methods to diagnose and treat cancer. Music by Kevin Macleod

Here is the original post:

Nanomedicine IGERT @ Northeastern

Read the Rest...

Andalusian Centre for Nanomedicine and Biotechnology (BIONAND)

§ May 30th, 2011 § Filed under Nano Medicine Comments Off on Andalusian Centre for Nanomedicine and Biotechnology (BIONAND)

http://www.bionand.es/en This new The Andalusian Centre for Nanomedicine and Biotechnology, BIONAND, is a mixed centre with stakes held by the Regional Ministry of Innovation, Science and Enterprise, the Regional Ministry of Health and the University of Malaga with the purpose to promote and encourage the development of an andalusian centre for excellence research in Nanomedicine.

See the rest here:

Andalusian Centre for Nanomedicine and Biotechnology (BIONAND)

Read the Rest...

International Stem Cell Corporation Reports First Quarter Revenue of $1.5 Million on Strong Initial Sales of Skin Care Products and Strong Growth…

§ May 29th, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Reports First Quarter Revenue of $1.5 Million on Strong Initial Sales of Skin Care Products and Strong Growth…

International Stem Cell Corporation Reports First Quarter Revenue of $1.5 Million on Strong Initial Sales of Skin Care Products and Strong Growth of Research Product Sales

International Stem Cell Corporation (OTCBB: ISCO) (ISCO) announces that revenue in the first quarter of 2011 was $1.5 million, compared with revenue of $273,000 in the first quarter of 2010. The increase was primarily due to $1.1 million in sales of Lifeline Skin Care products achieved in the pilot direct-to-consumer launch. Adding to the revenue growth was a 35% increase over the prior year in sales of human cell culture research products from subsidiary Lifeline Cell Technology.

ISCO also disclosed that it is delaying the filing of its Report on Form 10-Q for the period ending March 31, 2011 in order to resolve an accounting question as described below.

Shortly before the scheduled date for filing the 10-Q, ISCO identified an issue related to whether a technical interpretation of certain accounting guidance found in FASB ASC Topic 815, Derivatives and Hedging could require a change in the manner ISCO has historically accounted for the value of warrants originally issued as compensation to brokers working for the placement agent in the Company's 2007 initial public offering.

The accounting question is highly technical in nature and would have no impact on cash or revenues, but relates solely to the non-cash accounting for warrants issued several years ago. Rather than publish information that might be subject to further revision, ISCO has elected to delay the filing of its 10-Q until a decision can be made as to whether or not adjustments will need to be made and, if so, exactly what the accounting entries will be. The Company is committed to resolving this question as promptly as possible and will disclose the conclusion in the 10-Q.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, anticipated resolution of the accounting question, and opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, the application of accounting guidance, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110525005411r1&sid=14230&distro=ftp

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

Read the Rest...

International Stem Cell Corporation Enrolls First Donor in Program to Create New Parthenogenetic Stem Cell Lines in the United States

§ May 22nd, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Enrolls First Donor in Program to Create New Parthenogenetic Stem Cell Lines in the United States

CARLSBAD, Calif. -- (May 19, 2011) -- International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, has now enrolled the first U.S.-based donor in its program to establish a bank of clinical-grade human parthenogenetic stem cells (hpSCs) capable of being immune-matched to millions of patients.

Dr. Simon Craw, Vice President of ISCO with primary responsibility for building its UniStemCell Bank, said, “Enrolling our first donor is a key milestone towards our goal of creating a bank of clinical-grade pluripotent human stem cells with the ability to immune-match millions of patients. It is extremely exciting to start this new phase of development, and I look forward to making new clinical-grade hpSC lines available to medical researchers around the world.”

ISCO maintains the world’s largest collection of research-grade human parthenogenetic stem cell (hpSC) lines which it uses along with its partners and collaborators to investigate cellular therapies for a number of incurable human diseases.

ISCO previously announced it had successfully obtained the necessary regulatory approvals for obtaining human oocytes, including Institutional Review Board (IRB) approval and Stem Cell Research Oversight (SCRO) committee approval. Today’s announcement marks the next phase of development as the Company is now positioned to begin producing new clinical-grade hpSC lines.

These new cell lines will be ISCO’s first hpSCs to be produced in the United States in accordance with Good Manufacturing Practice (cGMP) specifications. The new cGMP hpSC lines will be uniquely valuable in therapeutic research and clinical development as cells or tissue derived from such cells can be used in human clinical trials.

ISCO’s scientific discoveries have resulted in the development of a unique new type of pluripotent stem cells that possess a number of distinct advantages over other types of human pluripotent stem cells. ISCO uses unfertilized oocytes to create human “parthenogenetic” stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, the potential production and benefits of stem cell lines, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation

760-940-6383

Kenneth C. Aldrich

Chairman

kaldrich@intlstemcell.com

Simon Craw, Ph.D.

Vice President

sc@intlstemcell.com

or:

Lippert/Heilshorn & Associates

Don Markley (dmarkley@lhai.com)

310-691-7100

# # #

Read the Rest...

International Stem Cell Corporation Chairman Comments on UC San Diego Study About Therapies Using Induced Pluripotent Stem Cells

§ May 22nd, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Chairman Comments on UC San Diego Study About Therapies Using Induced Pluripotent Stem Cells

International Stem Cell Corporation Chairman Comments on UC San Diego Study That Finds Therapies Using Induced Pluripotent Stem Cells Could Encounter Immune Rejection Problems

Scientists at the University of California, San Diego, announced last week that they had discovered that the class of stem cells known as "induced pluripotent stem cells" or "iPS" cells could cause an immune rejection problem when transplanted into mice. Scientists had hoped that these cells would have two big advantages over embryonic stem cells: they would not be controversial because their creation did not entail the destruction of human embryos; and, since the stem cells could be made from a particular patient’s skin cells, they could be used to make tissues that would not be rejected by the patient’s own immune system. Although responses in humans may be different, the discovery of an immune response in mice suggests that the second of these hopes may not be so easily realized.

That is disappointing news in many ways, but it illustrates what we at International Stem Cell Corporation (ISCO) think will be one of the great benefits of the Parthenogenetic Stem Cells our scientists have created and patented.

Parthenogenetic stem cells are not only pluripotent they also do not involve any destruction or damage to a viable human embryo. Since they are never fertilized (and can't become a child) they carry the DNA of only the egg donor and not the added DNA of a father or other sperm donor. This results in the possibility of matching these cells to large groups of people without causing immune response problems.

The science is a bit complicated, but the result is illustrated by the fact that the very first stem cell line ISCO created using its newest techniques has the potential to match the immune systems of over 50 million people. With the right donors, cell lines from as few as 50 donors (one respected scientist has said as few as 10 donors) could match a very large portion of the world's population. There is a lot of work yet to be done, but if one thinks of it as comparable to a blood bank, but for stem cells instead, the concept becomes quite exciting.

Lastly, even if iPS cells are never used for transplant therapy, they still have wonderful research potential, so those who hoped for medical breakthroughs using them should not despair. They are, and will be, very important, even though there are better pathways to transplant therapy.

Kenneth C. Aldrich - Chairman

International Stem Cell Corporation

Source: Press Release from the University of California San Diego http://www.eurekalert.org/pub_releases/2011-05/uoc--sft051211.php

Read the Rest...

International Stem Cell Corporation Scientists to Present Results of Recent Stem Cell Research on Central Nervous System and Liver Disease…..

§ May 22nd, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Scientists to Present Results of Recent Stem Cell Research on Central Nervous System and Liver Disease…..

ISCO Scientists to Present Results of Recent Stem Cell Research on Central Nervous System and Liver Diseases at Annual Meeting of American Society of Gene and Cell Therapy

International Stem Cell Corporation (OTCBB: ISCO) announced today that two of its leading scientists, Vice President Dr. Ruslan Semechkin and Director of Research and Therapeutic Development Dr. Nikolay Turovets, will present the results of their most recent experiments on the therapeutic use of human parthenogenetic stem cells (hpSCs) at the 14th Annual Meeting of American Society of Gene and Cell Therapy in Seattle.

ISCO's breakthrough discoveries have resulted in a new type of pluripotent human stem cells with distinct advantages over other human pluripotent stem cells. ISCO uses unfertilized oocytes to create human "parthenogenetic" stem cells. Like embryonic stem cells, hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike embryonic stem cells, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.

The data presented at the Seattle conference represents progress made in two specific areas: 1) the successful derivation of neuronal stem cell lines, which can potentially be used for treatment of degenerative diseases of the central nervous system (CNS), and 2) the differentiation of hpSCs towards liver cells and their progenitors.

Dr. Semechkin's oral presentation titled "Neural Stem Cells of Parthenogenetic Origin" will be on Thursday, May 19, 2011 at 4:15 pm.

Dr. Turovets poster presentation titled "An in vitro Analog of the Primitive Streak to Derive High-Purity Definitive Endoderm Lineages Uncontaminated with Undifferentiated Cells" will be on Saturday, May 21, 2011.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, the potential benefits of research programs and products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110517005739r1&sid=14230&distro=ftp

International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, PhD
Vice President, ISCO
CEO & President, Lifeline Skin Care
ras@intlstemcell.com

Or:
Nikolay Turovets, Ph.D.
Director, Research and Therapeutic Development
nturovets@intlstemcell.com

Read the Rest...

ELSI of Regenerative Nanomedicine, Part 4

§ May 21st, 2011 § Filed under Nano Medicine Comments Off on ELSI of Regenerative Nanomedicine, Part 4

JSB

Read more:

ELSI of Regenerative Nanomedicine, Part 4

Read the Rest...

Down to a Science – Nanomedicine in 10 minutes

§ May 19th, 2011 § Filed under Nano Medicine Comments Off on Down to a Science – Nanomedicine in 10 minutes

Dr. Tejal Desai discusses nanomedicine, nanotoxicology, and all else nano at the April 21st Down to a Science event

The rest is here:

Down to a Science - Nanomedicine in 10 minutes

Read the Rest...

International Stem Cell Corporation Launches New Marketing Campaign for Lifeline Skin CareTM Products

§ May 15th, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Launches New Marketing Campaign for Lifeline Skin CareTM Products

International Stem Cell Corporation (OTCBB: ISCO) today announced the Company's near-term marketing plans for products manufactured by its Lifeline Skin Care™ (Lifeline) subsidiary. Following the highly successful launch in late 2010 of Lifeline's first two products with sales that greatly exceeded expectations, Lifeline has now commenced a new phase in the marketing plan for its skin care products.

The first step in these initiatives is a series of briefings being conducted in New York City this week with editors at beauty magazines whose readership reflects the target user base for Lifeline's anti-aging skin care products. This will be followed by a series of targeted email offerings developed by Lifeline's marketing partner, The Mauldin Companies, culminating in a larger offering in June.

Lifeline's anti-aging products were developed by ISCO's scientific research team in collaboration with internationally recognized cosmetic experts. The first two products, a Day Serum and a Night Serum, both contain an extract from ISCO's proprietary human parthenogenetic stem cells which, in combination with vitamin complexes, provides major rejuvenating effects, including improvement in skin tone and elasticity, and improvement in the appearance of fine lines and wrinkles. These effects have been substantiated by clinical studies performed at industry-leading independent testing organizations.

Lifeline's premium product line includes the Recovery Night Moisture Serum and the Defensive Day Moisture Serum/SPF-15. These products are most commonly ordered together in a 2-pack, and can be purchased by visiting Lifeline's website athttp://www.lifelineskincare.com. The products are also available at selected luxury spas and physician's offices in the United States.

Dr. Ruslan Semechkin, President and CEO of Lifeline Skin Care, added that Lifeline plans to launch additional skin care products later this year, including an eye cream formulated with a proprietary stem cell derivative and a cleanser.

Lifeline is focusing its marketing on direct-to-consumer channels to highly targeted audiences with traditional print and media promotions planned for later in the year. The Company's goal is to generate favorable word-of-mouth through a network of satisfied customers, thereby building a community of users based on their shared experience of success with Lifeline's proprietary anti-aging products.

Ken Aldrich, Co-founder and Chairman of Lifeline's parent company, International Stem Cell Corporation, said, "The success of Lifeline Skin Care demonstrates that we can make a positive difference in people's lives today, while also providing an important source of revenue to support ISCO's development of stem cell therapies that may in the future result in treatment for many widespread human diseases."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, product introduction and marketing plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110512005363r1&sid=14230&distro=ftp

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or
Lifeline Skin Care, Inc.
Ruslan Semechkin, Ph.D., President & CEO
Vice President, ISCO
ras@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

Read the Rest...

Forward to Spring 2011 Issue

§ May 8th, 2011 § Filed under Nano Medicine Comments Off on Forward to Spring 2011 Issue

A Sense of Proportion

The world is a challenging place at the moment. Although visitors to Vitafoods are rightly focused on the product, pricing, regulatory and marketing problems and opportunities of their industries, the bigger picture matters to us too.

The widespread unrest in the Middle East with ‘people- power’ is changing long-standing political and strategic landscapes. Unrest in Tunisia and Egypt has led to changes of government and a coalition of nations has launched air attacks on military targets in Libya. Japan is still reeling from the tragedy of the recent earthquake, the resulting tsunami and desperate attempts to control damaged nuclear facilities at Fukishima. All this, while the global economy remains fragile (if not downright depressed) following the banking and financial crises of 2008/2009. Global markets, equities and currencies are volatile as traders and governments try to map a way forward out of the confusion.

In its own small way, the food industry reflects this crux. The rapidly rising price of staple food has been blamed for triggering much of the unrest in the Middle East and raising tensions elsewhere. Increased commodity, processing and packaging costs (due to rising oil prices) are impacting prices globally with the World Bank quoting a 15% increase in food prices in the four months between October 2010 and January 2011. In the UK, food price inflation is running at a reported 6.3% and in the USA, Feeding America reported a 46% increase in the number of people in the USA needing their assistance. Record numbers of floods, typhoons and unseasonal heat-waves, whether the result of global warming or some other factor, are impacting on the size and quality of agricultural crops and reducing the availability of good farmland. And all this at a time when scientists and agronomists are trying to find ways of meeting the challenge of feeding a rising world population which will reach 7 billion this year, up from 5 billion 20 years ago.

With disposable income likely to fall over the next 2 or 3 years, consumers will question every expenditure. Can the cost of dietary supplements and/or the additional premium of dietary supplements or functional foods be justified when staple ingredients need to be bought and the family needs to be fed?

Industry growth plans will have to address this fundamental question by investing in good marketing. Marketing that keeps the consumer interested, informed and persuaded of the benefits and value of its products, even when budgets are tight. But here’s another problem: just as consumer budgets are likely to be at their tightest, the strictures and limitations of EFSA’s rulings will begin to apply.

Our industry’s problems are trivial in comparison to much of what is happening in the world today. But for dietary supplement and functional foods manufacturers, and their customers, the storm clouds developing over Palma (where EFSA is based) still threaten to do serious damage. Only
by working constructively and creatively will we be able to navigate our way to a healthy and profitable future.

Henry Dixon
Commercial Director, Barrett Dixon Bell

Read the Rest...

Stevia rebaudiana: The Sweetener Power of Nature

§ May 8th, 2011 § Filed under Nano Medicine Comments Off on Stevia rebaudiana: The Sweetener Power of Nature

Reb A 97 GT the first class safe natural pure molecule of sweetness

The sweetness of Stevia’s leaves was well known for century and used by amerindians Guarinis which is called Kaâ-hè-é.

In 1899, the first detailled botanic ( and also sweetness) description was made by the swiss botanist Moisés Santiago Bertoni during his research in Eastern Paraguay.

The species Stevia rebaudiana, commonly known as sweetleaf, sweet leaf, sugarleaf, or simply stevia, is widely grown for its sweet leaves. As a sweetener and sugar substitute, stevia’s taste has a slower onset and longer duration than that of sugar, although some of its extracts may have a bitter or licorice-like aftertaste at high concentrations.

In 1931, the two french scientists Bridel and Lavielle have isolated and cristallised the compounds which were responsible of the sweet taste of Stevia rebaudiana, Bertoni. The exact chemical formula of steviolglycoside ( aglycone and glycoside) were publised in 1955. Now, more than 12 differents molecules, with the steviol aglycone, was isolated form differents variants of Stevia rebaudiana, B.

In 2008, the Coca-Cola Company with the giant agricultural processing Cargill have obtained the GRAS approval from the FDA for the Rebaudioside A with a purity > 97%.

In September 2009, the French government has followed the same way with a temporary autorisation as food additive for 2 years for the Rebaudioside A more than 97% of purity in order to wait the European Commission Directive.

In 2010, The NDA panel experts of .EFSA ( European Food Safety Agency) gave a positive opinion on the safety of Steviolglycosides ( a mixture of Rebaudioside A and Stevioside mainly) with a minimum purity of 95% expressed in dry basis.

This article is available in full in the Spring 2011 issue of Nutraceuticals Now

Read the Rest...

BENEO: Simply Healthier

§ May 8th, 2011 § Filed under Nano Medicine Comments Off on BENEO: Simply Healthier

BENEO, one of the leading manufacturers of functional ingredients, offers a range of solutions to enable sugar reduction in food products and prides itself on producing innovative ingredient solutions for food manufacturers. By concentrating on the taste, functionality and qualitative elements of a product, BENEO has developed its agglomerated sweeteners which are simple to integrate and provide a multitude of benefits. Here, Dr Thomas Walter, Head of Business Development at BENEO, provides insight into how its agglomerated sweeteners can be incorporated into products to provide sweetening solutions that are healthy and easy to use.

A review of the Mintel trend forecasts for 2011 shows that manufacturers are concentrating their efforts on product reformulations to ensure they meet the growing consumer demand for healthier nutrition. One of the major topics, sugar reduction, is still very high up on the food industry’s agenda. This issue is particularly pertinent as the entire sector prepares for the upcoming approval of Stevia, which claims to have mastered the delicate balancing act between calorie reduction and naturalness like no other intensive sweetener. The successful switch from saccharine, HFCS, fructose and glucose will allow food producers to make use of these ingredients in order to optimize their product offering with ease.

The use of agglomerated sweeteners is mainly for technological reasons. Agglomerates do not tend to dust or build up electrostatic energy and have a distinct flowability. This provides the producer with additional benefits, such as ease of transportation and use when measuring or filling. As they don’t absorb moisture, agglomerates can also be stored more easily. They dissolve quickly in fluids without forming lumps and, when consumed on their own, have a non-sandy texture in the mouth. The versatility of these agglomerates make them an excellent choice for use within ready-to-use instant drinks, compressed tablets, chewing gum and granulates, which are consumed with no water.

When several active and functional ingredients are used for the agglomeration, further advantages can be found. During the course of the agglomeration process, all of the elements are distributed evenly in the mixture, no matter how much or how little is used. An even distribution of the ingredient is therefore guaranteed, whether this is the sweet characteristic of an intensive sweetener such as Stevia, or the nutritionally enhanced profile of vitamins, or prebiotic fibres, such as inulin.

This article is available in full in the Spring 2011 issue of Nutraceuticals Now

Read the Rest...

Aenova Group: New Effervescent Product

§ May 8th, 2011 § Filed under Nano Medicine Comments Off on Aenova Group: New Effervescent Product

The new product range from the Aenova Group offers a selection of high-quality and exclusive effervescent products, thus extending the company’s range and offering its customers the opportunity to stand out from the established mass market.

The new high-quality effervescent product range from the Aenova Group expands its portfolio and emphasises its position as one of the world’s largest suppliers of solid oral administration forms for the pharmaceutical and healthcare industry. The Aenova Group is one of the few companies in the branch to offer a full-service portfolio encompassing the purchasing of raw materials, analytics, packaging and logistics, alongside manufacturing and production. The ongoing objective of the company is the continual development of new product concepts and products which are tailored to the needs of customers and markets. Thus, since May 2010, Aenova has been offering a standard range of a variety of dietary supplements which cover different indication ranges. This standard product range has enabled the company to expand its customer services and create time-saving and cost-effective solutions for the international dietary supplements market.

With the new effervescent product range, Aenova has provided a diverse selection of high-quality and unique effervescent products. High-quality products which demonstrate particularly good market potential and correspond to current trends are developed on the basis of detailed market analyses, coupled with longstanding know-how and in-depth market knowledge.

This article is available in full in the Spring 2011 issue of Nutraceuticals Now

Read the Rest...

International Stem Cell Corporation Chairman Presents Summary of Achievements at Annual Shareholders’ Meeting

§ May 8th, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Chairman Presents Summary of Achievements at Annual Shareholders’ Meeting

CARLSBAD, Calif. (May 05, 2011) - At the annual shareholders meeting of International Stem Cell Corporation (OTCBB:ISCO) on May 3, 2011, Kenneth Aldrich, Chairman and co-founder of ISCO conducted a presentation to shareholders that included the following remarks:

Good morning to all our shareholders and friends of ISCO. Let me make just a few comments about where we are and the progress we have made over the last year. All of the developments and news I will discuss were announced in the past 12 months, but with the passage of time it is easy to lose track of how much progress ISCO has actually made. I won’t mention everything—we don’t have that much time, but some highlights will, I hope, help put these recent achievements into perspective.

A little less than a year ago, in June 2010, our first parthenogenetic patent application was formally approved by the US Patent Office. More applications are pending, but this approval established ISCO as the lawful owner of the rights to produce human stem cell lines through parthenogenesis. That is a platform on which we expect to build for a long time.

Also in June we eliminated all of our outstanding corporate debt and we remain debt free.

In July we announced the signing of a distribution contract with Sristi Biosciences, a major seller of research products in India, which continues the international commercial expansion of our Lifeline Cell Technology® brand.

In October we announced the first steps toward the formation of a major funded collaboration in India with Insight Bioventures India Private Limited (IBVI) to develop treatments for corneal damage and retinal disease. Planning for that work is ongoing and the Executive Director of Insight Bioventures has flown in from India to meet with us today, so we remain very optimistic about this project.

In November, we presented the results of scientific studies demonstrating a new and better method for differentiating our parthenogenetic cells into liver cells, a critical step toward using them to treat liver disease.

In November and December we launched the first test marketing runs of our new skin crème products, first to our own shareholders and friends, then to a select mailing list developed by our marketing partner, John Mauldin. Those resulted in sales of over 7,000 bottles of our new products.

In December we established $25 million financing commitment that provides access to capital on an as-needed basis over a three year period, but never requires the sale of stock unless we think it will benefit the company and its shareholders. This agreement provides us a high degree of flexibility in meeting our financial needs.

In January 2011 we announced publication of peer-reviewed studies further validating the functional equivalency of our parthenogenetic stem cells with embryonic stem cells. These studies confirm our ability to benefit from much of the millions of dollars of research on embryonic stem cells over the last decade. In short, we have a running start in the search for cures.

Throughout the year we have made steady progress in development of liver cells and liver precursor cells, culminating in an announcement in April of this year that we had successfully completed the first in a series of pre-clinical tests of parthenogenetically derived liver cells.

Last, but by no means least, we have received the necessary approvals for creating new Parthenogenetic Stem Cell Lines in the United States. These will be clinical grade lines suitable for human trials, and are the first major step in this country to begin building a “Bank” of stem cells enabling the matching of immune systems of millions of people worldwide, with the potential to eliminate or reduce the harmful effects of immune suppressing drugs that would normally have to be used with stem cell transplant procedures.

All of these news stories and more are available on our website along with presentations we have made recently to investors in the US and Europe. On behalf of the Board of Directors and everyone at ISCO, I thank you for your support.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, product introduction plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contact:

International Stem Cell Corporation

Kenneth C Aldrich, Chairman

760-940-6383

kaldrich@intlstemcell.com

# # #

Read the Rest...

Nanomedicine: Release of neurological drugs

§ May 5th, 2011 § Filed under Nano Medicine Comments Off on Nanomedicine: Release of neurological drugs

Nanomedicine Catalytic: Release of Neurological drugs

Read this article:

Nanomedicine: Release of neurological drugs

Read the Rest...

International Stem Cell Corporation Completes First Series of Pre-Clinical Testing of Hepatocytes Derived from Human Parthenogenetic Stem Cells

§ May 1st, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Completes First Series of Pre-Clinical Testing of Hepatocytes Derived from Human Parthenogenetic Stem Cells

Data from successful animal study using liver cells derived from human parthenogenetic stem cells to be presented at two upcoming scientific conferences

Company also announces collaboration with Cedars-Sinai Medical Center for liver disease research, and completion of research on cytochrome P450 activity

International Stem Cell Corporation (OTCBB:ISCO) (ISCO) announces successful completion of the first series of preclinical testing of hepatocytes derived in the lab from human parthenogenetic stem cells (hpSC). In the transplantation mouse model, inoculated cells were capable of engrafting and surviving in specific niches within the liver, and were further developing into cells with essential hepatocyte-like features. Moreover, the transplanted cells could be identified in recipient tissue for a prolonged period of time.

The findings of these studies will be presented at the annual meeting of American Society of Gene & Cell Therapy, May 18-21 in Seattle, and at the International Society for Stem Cell Research annual conference, June 15-18 in Toronto.

"These results mark the achievement of a key milestone in our preclinical research," said Andrey Semechkin, Ph.D., ISCO's Chief Executive Officer. "Specifically, we have perfected the technique to transplant hepatocytes, an extremely fragile cell type, into the liver of animals, which is an easily injured organ. This preclinical research helps us develop our collaborations with clinics."

Nikolay Turovets, Ph.D., ISCO's Director of Research and Therapeutic Development commented "The next phase of research is to conduct experiments to demonstrate the ability of the transplanted cells to perform the vital functions of normal hepatocytes and, accordingly, their ability to modify disease by restoring the missing function of a patient's diseased liver."

The Company also announces the signing of a joint collaboration agreement with Cedars-Sinai Medical Center in Los Angeles to conduct research to develop therapies for liver diseases, in particular urea cycle disorders. Jeffrey Fair, MD., a liver transplant surgeon and Director of Translational Research for the Cedars-Sinai Comprehensive Transplant Center and Department of Surgery, will lead the Cedars-Sinai research team.

Dr. Fair said, "Urea cycle disorders are genetic deficiencies of liver function, which mostly affect newborns and oftentimes cause catastrophic neurological injury. It has been shown that transplantation of donor hepatocytes can save patient lives. Therefore, derivation of hepatocytes from hpSCs that can be immune-matched to the patient is a very pressing goal."

The Company also announces the completion of research focused on the investigation of cytochrome P450 activity and corresponding genes in hepatocytes derived from hpSC. According to the results, the differentiation technology developed by ISCO allows the creation of hepatocytes in the fetal stage of development. This research may contribute to the design of a product for future drug testing and discovery.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110426005697r1&sid=14230&distro=ftp

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or
Nikolay Turovets, Ph.D.
Director, Research and Therapeutic Development
nturovets@intlstemcell.com

Read the Rest...

International Stem Cell Corporation Updates on Marketing Strategy of Its Subsidiary Lifeline Skin Care

§ April 24th, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Updates on Marketing Strategy of Its Subsidiary Lifeline Skin Care

International Stem Cell Corporation (OTCBB:ISCO) http://www.internationalstemcell.com, a California-based biotechnology company focused on therapeutic and research products, announced today the selection of the Richards Partners as agency of record for its wholly owned subsidiary Lifeline Skin Care, Inc. ("Lifeline"). Lifeline offers luxury anti-aging skin care products based on its proprietary stem cell technology. Based in Dallas, the Richards Partners is the nation's largest independent branding agency.

Lifeline's skin care products were developed by a team of ISCO research scientists in collaboration with world-renowned cosmetic experts, and offer a comprehensive approach to skin care using patent pending moisture serums for day and night use. Made with human parthenogenetic stem cell extracts, the serums deliver anti-aging benefits, resulting in healthier and younger-looking skin. These products were launched in November 2010 and are available for purchase through the http://www.lifelineskincare.com website and selected luxury spas across the United States.

Adding Richards Partners to the Lifeline Skin CareTM team is part of Lifeline's plan to build on its initial successful product launch last year, and the Web based sales that have followed, by initiating a series of new marketing campaigns to further develop the Lifeline Skin CareTMbrand identity. These new marketing initiatives include traditional print and news media campaigns, as well as a new digital strategy focused on Internet and social media. "We are looking forward to working closely with the Richards Partners and leveraging their expertise in these areas to enhance the profile of Lifeline Skin CareTM and its revolutionary new skin care products," says Lifeline CEO Ruslan Semechkin, PhD. "Building a globally recognizable brand is a long-term process and this is an important step towards creating Lifeline's name. We believe this is a good time to begin these campaigns and continue our sales momentum resulting from our successful initial launch," Dr. Semechkin continued.

As previously announced the Mauldin Group, Lifeline's marketing partner, will be managing the day to day relationship with the Richards Partners and planning additional direct marketing initiatives similar to the successful initial launch in 2010. Tiffani Mauldin-Frederick, marketing partner of Lifeline Skin CareTM, says, "We're excited about working together with Richards Partners. We believe the collaboration will provide additional momentum and increase brand recognition for Lifeline Skin CareTM and help educate the public about the revolutionary science behind these products."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product introduction plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care, anti-aging

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110419005649r1&sid=14230&distro=ftp

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com

or
Lifeline Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice President, ISCO
ras@intlstemcell.com

Read the Rest...

Part 1: Nanomedicine Expert Ralph Merkle, PhD

§ April 18th, 2011 § Filed under Nano Medicine Comments Off on Part 1: Nanomedicine Expert Ralph Merkle, PhD

Institute for Molecular Manufacture Senior Fellow on the development of nanofactories and the implications of building "medical nanorobots" that can keep people alive and healthy, thereby radically extending lifespans. More information at manhattanbeachproject.com Updates at http

Go here to read the rest:

Part 1: Nanomedicine Expert Ralph Merkle, PhD

Read the Rest...

Proactiveinvestors Completes First European Presentations with NeoStem and International Stem Cell Corp

§ April 3rd, 2011 § Filed under Nano Medicine Comments Off on Proactiveinvestors Completes First European Presentations with NeoStem and International Stem Cell Corp

Proactiveinvestors completed its first investor forums in mainland Europe, in partnership with Milestone Media, last week, hosting presentations in Zurich and Munich with US listed companies NeoStem (AMEX:NBS) and International Stem Cell Corporation (OTC:ISCO).

Both investor forums were a great success, with notable attendees including Infidar Investment Advisory, BB Bellevue Asset Management, Centrum Bank, Taylor Wessing, BVMW and UBS Global Asset Management.

NeoStem’s CEO and Chairman Robin Smith updated investors on the company’s adult stem cell operations in the U.S., network of adult stem cell therapeutic providers in China, and recent acquisition of a 51% interest in a profitable Chinese generic pharmaceutical manufacturing company.

The company is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally.

NeoStem was recently given an initial "outperform" rating from US equity research firm Cowen, based on recent acquisitions and tie ups strengthening the company's adult stem cell banking capabilities.

Ken Aldrich, Chairman and Co-Founder of International Stem Cell Corporation also had plenty to introduce to European audiences. The California-based biotechnology company is focused on the therapeutic applications of human stem cells and the development and commercialization of cell-based research and cosmetic products.

The company’s core technology, Parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes. This technique avoids ethical issues associated with the use or destruction of viable human embryos and can be a source of therapeutic cells that minimize or eliminate immune rejection after transplantation into the patient.

Read the Rest...

« Older Entries Newer Entries »



Page 49«..1020..48495051..»